Cross S E, Richards S K, Clark A, Benest A V, Bates D O, Mathieson P W, Johnson P R V, Harper S J, Smith R M
Academic Renal Unit, Southmead Hospital, University of Bristol, Bristol, UK.
Diabetologia. 2007 Jul;50(7):1423-32. doi: 10.1007/s00125-007-0670-8. Epub 2007 May 3.
AIMS/HYPOTHESIS: Rapamycin, part of the immunosuppressive regimen of the Edmonton protocol, has been shown to inhibit vascular endothelial growth factor (VEGF) production and VEGF-mediated survival signalling in tumour cell lines. This study investigates the survival-promoting activities of VEGF in human islets and the effects of rapamycin on islet viability.
Levels of VEGF and its receptors in isolated human islets and whole pancreas was determined by western blotting and immunostaining. Islet viability following VEGF or immunosuppressive drug treatment was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Islet VEGF release was measured by ELISA. Mouse islets infected with an adenovirus expressing the gene for VEGF were transplanted syngeneically into streptozotocin-induced diabetic mice, with blood glucose levels measured three times per week.
Isolated human islets produced multiple isoforms of VEGF and VEGF receptors 1, 2 and 3 and the coreceptor neuropilin 1. Exogenous VEGF (10 ng/ml) prevented human islet death induced by serum starvation, which suggests that VEGF can act as a survival factor for human islets. Transplantation of mouse islets infected with a VEGF-expressing adenovirus in a syngeneic model, improved glycaemic control at day 1 post-transplantation (p < 0.05). Rapamycin at 10 and 100 ng/ml significantly reduced islet VEGF release (by 37 +/- 4% and 43 +/- 6%, respectively; p < 0.05) and at 100 ng/ml reduced islet viability (by 36 +/- 9%) and insulin release (by 47 +/- 7%, all vs vehicle-treated controls; p < 0.05). Tacrolimus had no effect on islet VEGF release or viability.
CONCLUSIONS/INTERPRETATION: Our data suggest that rapamycin may have deleterious effects on islet survival post-transplantation, both through a direct effect on islet viability and indirectly through blockade of VEGF-mediated revascularisation.
目的/假设:雷帕霉素是埃德蒙顿方案免疫抑制方案的一部分,已被证明可抑制肿瘤细胞系中血管内皮生长因子(VEGF)的产生以及VEGF介导的生存信号传导。本研究调查了VEGF在人胰岛中的促生存活性以及雷帕霉素对胰岛活力的影响。
通过蛋白质印迹法和免疫染色法测定分离的人胰岛和整个胰腺中VEGF及其受体的水平。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)法测定VEGF或免疫抑制药物处理后胰岛的活力。通过酶联免疫吸附测定法(ELISA)测量胰岛VEGF释放量。将感染表达VEGF基因的腺病毒的小鼠胰岛同基因移植到链脲佐菌素诱导的糖尿病小鼠体内,每周测量三次血糖水平。
分离的人胰岛产生多种VEGF异构体以及VEGF受体1、2和3和共受体神经纤毛蛋白1。外源性VEGF(10 ng/ml)可防止血清饥饿诱导的人胰岛死亡,这表明VEGF可作为人胰岛的生存因子。在同基因模型中,移植感染表达VEGF腺病毒的小鼠胰岛,在移植后第1天改善了血糖控制(p < 0.05)。10和100 ng/ml的雷帕霉素显著降低胰岛VEGF释放(分别降低37 +/- 4%和43 +/- 6%;p < 0.05),100 ng/ml时降低胰岛活力(降低36 +/- 9%)和胰岛素释放(降低47 +/- 7%,均与载体处理的对照组相比;p < 0.05)。他克莫司对胰岛VEGF释放或活力无影响。
结论/解读:我们的数据表明,雷帕霉素可能对移植后胰岛存活产生有害影响,既通过对胰岛活力的直接作用,也通过阻断VEGF介导的血管再生间接产生影响。